Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahak Arora

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
European Journal of Pharmacology|February 27, 2022
mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitisMahak Arora, Nikolina Kutinová Canová, Hassan Farghali
Casopis Lekaru Ceskych|June 21, 2022
Statins and liverJiří Hlušička, Mahak Arora, Radan Brůha, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|April 13, 2022
Differentiated modulation of signaling molecules AMPK and SIRT1 in experimentally drug-induced hepatocyte injuryLea Njeka Wojnarova, Nikolina Kutinova Canova, Mahak Arora, et al.
European Journal of Pharmacology|July 5, 2025
Effectiveness and safety of the SREBP1/2 inhibitor, fatostatin, in a preclinical model of metabolic dysfunction-associated steatotic liver disease progressionMahak Arora, Nikolina Canová, Tijana Šopin, et al.
Frontiers in Pharmacology|February 19, 2025
Effects of celastrol on the heart and liver galaninergic system expression in a mouse model of Western-type diet-induced obesity and metabolic dysfunction-associated steatotic liver disease and steatohepatitisNikolina Canová, Jana Šípková, Mahak Arora, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 8, 2023
Pharmacological effects of mTORC1/C2 inhibitor in a preclinical model of NASH progressionMahak Arora, Zuzana Pavlíková, Tomáš Kučera, et al.
Frontiers in Pharmacology|November 13, 2025
Regulation of inflammatory pathways by cannabigerol in the collagen induced arthritis model in ratsMonika Šteigerová, Michaela Sklenárová, Mykhaylo Bazyuk, et al.
Frontiers in Pharmacology|March 6, 2024
Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in ratsJiří Pozniak, Pavel Ryšánek, David Smrčka, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 2, 2026
Empagliflozin in combination with trandolapril but not with triple therapy improves glucose and lipid metabolism in non-diabetic hypertensive modelSilvie Hojná, Hana Malínská, Martina Hüttl, et al.
Molecular Pharmaceutics|July 4, 2025
Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in RatsPavel Ryšánek, Petr Jelínek, Hynek Housar, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
European Journal of Pharmacology|February 27, 2022
mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitisMahak Arora, Nikolina Kutinová Canová, Hassan Farghali
Casopis Lekaru Ceskych|June 21, 2022
Statins and liverJiří Hlušička, Mahak Arora, Radan Brůha, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|April 13, 2022
Differentiated modulation of signaling molecules AMPK and SIRT1 in experimentally drug-induced hepatocyte injuryLea Njeka Wojnarova, Nikolina Kutinova Canova, Mahak Arora, et al.
European Journal of Pharmacology|July 5, 2025
Effectiveness and safety of the SREBP1/2 inhibitor, fatostatin, in a preclinical model of metabolic dysfunction-associated steatotic liver disease progressionMahak Arora, Nikolina Canová, Tijana Šopin, et al.
Frontiers in Pharmacology|February 19, 2025
Effects of celastrol on the heart and liver galaninergic system expression in a mouse model of Western-type diet-induced obesity and metabolic dysfunction-associated steatotic liver disease and steatohepatitisNikolina Canová, Jana Šípková, Mahak Arora, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 8, 2023
Pharmacological effects of mTORC1/C2 inhibitor in a preclinical model of NASH progressionMahak Arora, Zuzana Pavlíková, Tomáš Kučera, et al.
Frontiers in Pharmacology|November 13, 2025
Regulation of inflammatory pathways by cannabigerol in the collagen induced arthritis model in ratsMonika Šteigerová, Michaela Sklenárová, Mykhaylo Bazyuk, et al.
Frontiers in Pharmacology|March 6, 2024
Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in ratsJiří Pozniak, Pavel Ryšánek, David Smrčka, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 2, 2026
Empagliflozin in combination with trandolapril but not with triple therapy improves glucose and lipid metabolism in non-diabetic hypertensive modelSilvie Hojná, Hana Malínská, Martina Hüttl, et al.
Molecular Pharmaceutics|July 4, 2025
Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in RatsPavel Ryšánek, Petr Jelínek, Hynek Housar, et al.
Pageof 2